MedPath

Second Molecular Event Identification by Exome Sequencing for Intellectually Disabled Patients Carrying 16p13.11 CNVs

Conditions
Intellectual Disability
Interventions
Genetic: Exome sequencing
Registration Number
NCT03644797
Lead Sponsor
Hospices Civils de Lyon
Brief Summary

16p13.11 copy number variations are considered as predisposition factors for neurodevelopmental disorders but can be inherited from normal parents. SEESIC aims at identifying seond molecular events by exome sequencing that could modulate the phenotype and explain familial discrepancies.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
18
Inclusion Criteria
  • Patients presenting intellectual disability
  • Patients carrying a 16p13.11 copy number variant
  • Blood DNA available without re sampling for the patient and his parents.
  • Consent for genetics analysis already for the patient and his parents.
Read More
Exclusion Criteria
  • Other diagnosis for intellectual disability (apart 16p13.11 copy number variant) already posed
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
PatientsExome sequencingPatients presenting intellectual disability and previously diagnosed as carriers of a 16p13.11 copy number variant using Cytogenetic Micro Array.
Primary Outcome Measures
NameTimeMethod
Second pathogenic molecular event on exome data4 months

Number of participants diagnosed as carrier of a (likely) pathogenic variation beyond 16p13.11 CNV through exome sequencing according to ACMG 2015 guidelines

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hôpital Femme Mère Enfant (Groupement Hospitalier Est)

🇫🇷

Bron, France

© Copyright 2025. All Rights Reserved by MedPath